A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs NDV 3 (Primary)
- Indications Candidiasis; Staphylococcal infections
- Focus Pharmacodynamics
- 04 Aug 2017 Status changed from recruiting to suspended.
- 11 May 2017 Planned End Date changed from 29 Dec 2017 to 29 Dec 2018.
- 11 May 2017 Planned primary completion date changed from 15 Nov 2017 to 29 Dec 2018.